Teladoc Exceeds Q2 Revenue Expectations, Sets New FY22 Guidance

Teladoc Health (TDOC) reported Q2 CY2025 results exceeding revenue expectations, with sales of $631.9 million, a 1.6% YoY decline. The company's GAAP loss of $0.19 per share was 27.8% above analysts' consensus estimates. Teladoc slightly lifted its revenue guidance for the full year to $2.52 billion at the midpoint and expects a GAAP loss of $1.18 per share.

Teladoc Health Inc. (NYSE: TDOC) reported its second-quarter (Q2) 2025 financial results, revealing a 1.6% year-over-year (YoY) decline in revenue to $631.9 million, which exceeded analysts' expectations [1]. The company's GAAP loss of $0.19 per share was 27.8% above the consensus estimate of $0.26 per share, driven by a 4% YoY increase in the Integrated Care segment and a 9% YoY decline in the BetterHelp segment [2].

The company's adjusted EBITDA, a measure of operating profitability, fell 23% to $69.3 million, but this was also above the consensus estimate of $63.50 million [1]. Teladoc attributed the revenue decline primarily to challenges in its direct-to-consumer market segment, BetterHelp, which saw a 9% YoY decrease in revenue to $240.4 million [2].

Teladoc's CEO, Chuck Divita, expressed satisfaction with the company's performance, stating that the results reflect "continued disciplined execution and builds on our solid results from the first quarter" [2]. The company also secured a $300 million credit facility to enhance financial flexibility [1].

For the third quarter (Q3) 2025, Teladoc expects revenue between $614 million and $636 million, with a GAAP loss of $0.20 to $0.35 per share. The full-year 2025 revenue guidance was lifted to $2.52 billion at the midpoint, with a GAAP loss of $1.18 per share [2].

Analysts remain cautiously optimistic, with an average rating of "hold" and a breakdown of recommendations including 5 "strong buy" or "buy," 22 "hold," and no "sell" or "strong sell" [1]. The median 12-month price target for Teladoc Health Inc. stands at $8.38, about 2.1% above its July 28 closing price of $8.20 [1].

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_PLX9CB307:0-teladoc-q2-revenue-down-2-but-beats-expectations/
[2] https://www.investing.com/news/earnings/teladoc-shares-jump-6-on-narrower-than-feared-q2-loss-revenue-beats-93CH-4158464